Clinical Handbook of Psychotropic Drugs
Hogrefe Publishing (Verlag)
978-0-88937-593-2 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Accurate and up-to-date
Comparison charts help decision-making
Icons and full color
Available in print and online
Downloadable patient info sheets
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition:
Neuroscience-based nomenclature - added to product availability tables
Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also updates to SSRI use in pregnancy and antidepressant augmentation strategies
Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment
Mood stabilisers chapter sections on Lithium and Anticonvulsants have been extensively revised
New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)
Ric M. Procyshyn; BScPharm, MSc, PharmD, PhD; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada. Kalyna Z. Bezchlibnyk-Butler; BScPharm, FCSHP; Toronto, ON, Canada. J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine
Dopamine Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine
Reuptake Inhibitor (SNRI) * Serotonin-2 Antagonists / Reuptake
Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor
(SPARI) * Serotonin Modulator and Stimulator (SMS) * Noradrenergic /
Specific Serotonergic Antidepressants (NaSSA) * Nonselective
Cyclic Antidepressants * Reversible Inhibitor of MAO-A (RIMA) * Irreversible
Monoamine Oxidase (A&B) Inhibitors (MAOIs) * Irreversible
MAO-B Inhibitor * GABAA Receptor Positive Modulator * NMDA
Receptor Antagonist * Effects of Antidepressants on Neurotransmitters
/ Receptors * Pharmacological Effects of Antidepressants on
Neurotransmitters / Receptors * Frequency of Adverse Reactions to
Antidepressants at Therapeutic Doses * Antidepressant Doses and
Pharmacokinetics * Switching Antidepressants * Antidepressant
Augmentation Strategies
Electroconvulsive Therapy (ECT)
Bright Light Therapy (BLT)
Repetitive Transcranial Magnetic Stimulation (rTMS)
Antipsychotics
Second-Generation Antipsychotics / SGAs * Third-Generation
Antipsychotic / TGA * 5-HT21 Inverse Agonist Antipsychotic * First-
Generation Antipsychotics / FGAs * Effects of Antipsychotics on
Neurotransmitters / Receptors * Pharmacological Effects of Antipsychotics
on Neurotransmitters / Receptor Subtypes * Relative Tolerability
Profiles of Anti-psychotics * Frequency of Adverse Reactions
to Antipsychotics at Therapeutic Doses * Antipsychotic Doses and
Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of
Long-Acting IM Antipsychotics * Switching Antipsychotics *
Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects and Their
Management
Extrapyramidal Adverse Effects of Antipsychotics * Treatment
Options for Extrapyramidal Side Effects * Effects on Extrapyramidal
Symptoms * Comparison of Agents for Treating Acute Extrapyramidal
Side Effects * Doses and Pharmacokinetics of Agents for Treating
Acute Extrapyramidal Side Effects
Anxiolytic (Antianxiety) Agents
Benzodiazepines * Comparison of the Benzodiazepines * Buspirone
Hypnotics / Sedatives
L-Tryptophan * Comparison of Hypnotics / Sedatives
Mood Stabilizers
Lithium * Anticonvulsants * Comparison of Anticonvulsants *
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic
Doses
Drugs for ADHD
Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD *
2 Agonists * Augmentation Strategies in ADHD
Drugs for Treatment of Dementia
Cholinesterase Inhibitors * Memantine * Comparison of Drugs for
Treatment of Dementia
Sex-Drive Depressants
Comparison of Sex-Drive Depressants
Drugs of Abuse
Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols
* Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam
(Rohypnol) * Nicotine / Tobacco
Treatment of Substance Use Disorders
Acamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone *
Pharmacotherapy for Nicotine / Tobacco Use Disorder * Comparison
of Treatments for Nicotine / Tobacco Use Disorder
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents * Anti-Inflammatory Agents * Cannabinoids * Dopaminergic
Agents * GABA Agents / Anticonvulsants *
Hormones * NMDA Agents * 5-HT3 Antagonists * Miscellaneous
Natural Health Products
Pharmacogenetic Information for Common Psychotropic Drugs
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient Information Sheets
Index of Drugs
| Erscheinungsdatum | 27.09.2021 |
|---|---|
| Verlagsort | Toronto |
| Sprache | englisch |
| Maße | 279 x 216 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
| ISBN-10 | 0-88937-593-3 / 0889375933 |
| ISBN-13 | 978-0-88937-593-2 / 9780889375932 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
